rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    NBIX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Why Neurocrine Biosciences (NBIX) Could Be 20% Undervalued On INGREZZA Momentum
      18h agoYahoo FinanceNBIX
      Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid Choice
      Nov 9Yahoo FinanceNBIX
      All You Need to Know About Neurocrine (NBIX) Rating Upgrade to Buy
      Nov 9Yahoo FinanceNBIX
      Wall Street Analysts See a 25.53% Upside in Neurocrine (NBIX): Can the Stock Really Move This High?
      Nov 9Yahoo FinanceNBIX
      Neurocrine Biosciences Stock: Breaking Down A Solid Quarter (NASDAQ:NBIX)

      Neurocrine Biosciences posts strong Q3 earnings as INGREZZA drives growth and rare disease expansion gains traction. Find out why NBIX stock is a buy.

      Nov 5Seeking AlphaNBIX
      Neurocrine Biosciences: 3 Growth Drivers And An Attractive Valuation (NASDAQ:NBIX)

      Neurocrine Biosciences offers growth and value with strong INGREZZA sales, new drug momentum, and 2027 catalysts. Learn more about NBIX stock here.

      Nov 4Seeking AlphaNBIX
      Neurocrine Biosciences: Up 15% After Q3, The Research Engine Is Still Almost Free (NBIX)

      Neurocrine Biosciences remains a Buy as strong Q3 results and an underappreciated pipeline lift fair value. Read more on NBIX stock here.

      Nov 4Seeking AlphaNBIX
      Guggenheim raises Neurocrine Biosciences price target on revenue beat
      Nov 4Investing.comNBIX
      Neurocrine Biosciences director George Morrow sells $2.3M in stock
      Nov 4Investing.comNBIX
      Neurocrine Biosciences advances 13% after Q3 beat, raised guidance (NBIX:NASDAQ)

      Neurocrine Biosciences stock jumped 13% after Q3 earnings beat estimates and sales guidance rose.

      Nov 3Seeking AlphaNBIX
      Why is Neurocrine Biosciences stock surging today?
      Nov 3Investing.comNBIX
      Is Neurocrine Biosciences (NBIX) A Bargain On Raised INGREZZA Guidance?

      Neurocrine Biosciences (NBIX) just delivered a busy quarter, with better than expected earnings, strong year over year revenue growth, and a higher full year sales outlook for INGREZZA following solid uptake across its key franchises. Despite the strong third quarter, Neurocrine Biosciences shares have eased over the past three months, with a 90 day share price return that declined 12.47%. However, the 3 year total shareholder return of 27.49% and 5 year total shareholder return of 55.34%...

      Nov 3Yahoo FinanceNBIX
      Neurocrine stock rises on Q3 beat, guidance hike (NBIX:NASDAQ)
      Nov 3Seeking AlphaNBIX
      Neurocrine Biosciences (NBIX) Starts Phase 2 Alzheimer’s Study And Expands Doctor Education
      Nov 3Yahoo FinanceNBIX
      Neurocrine Biosciences (NBIX) Stock Looks Cheap After Its 55% Five Year Run
      Nov 3Yahoo FinanceNBIX
      Biopharma Stock Neurocrine Biosciences Soars. It’s More Than Just Ingrezza.

      Neurocrine Biosciences stock jumped after strong quarterly earnings. Its gains are fueled by more than just its flagship drug, Ingrezza.

      Nov 3Barron'sNBIX
      Neurocrine Biosciences Delivers Strong Q3 on Vykat Rebound, RBC Says
      Nov 3Yahoo FinanceNBIX
      Cantor Fitzgerald reiterates Neurocrine Bio stock rating on revenue growth
      Nov 3Investing.comNBIX
      Neurocrine: Q3 Earnings Snapshot
      Nov 3Yahoo FinanceNBIX
      Neurocrine Biosciences Q3 Earnings Call Highlights
      Nov 3Yahoo FinanceNBIX
      Neurocrine Q3 2026 slides: revenue tops $1.1B, INGREZZA guidance raised
      Nov 2Investing.comNBIX
      Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top Estimates
      Nov 2Yahoo FinanceNBIX
      Neurocrine earnings beat by $1.38, revenue topped estimates
      Nov 2Investing.comNBIX
      Neurocrine (NBIX) Reports Q3 Earnings: What Key Metrics Have to Say
      Nov 2Yahoo FinanceNBIX
      Neurocrine Biosciences Q3 Adjusted Earnings, Revenue Rise
      Nov 2Yahoo FinanceNBIX
      Neurocrine earnings in focus as Ingrezza pricing pressure looms
      Nov 2Investing.comNBIX
      Where Will Neurocrine Biosciences Be in 5 Years? | The Motley Fool

      Neurocrine's expanding drug portfolio could drive substantial growth through 2031.

      Oct 25The Motley FoolNBIX
      Expert Publication On PWS Treatment Could Be A Game Changer For Neurocrine Biosciences (NBIX)

      Neurocrine Biosciences reported an expert publication on hyperphagia in Prader Willi syndrome that frames the condition as a complex neurobiological disorder and highlights VYKAT XR as the first FDA approved therapy for this symptom in PWS. The piece reinforces VYKAT XR as a core element of comprehensive, multidisciplinary PWS care, which speaks directly to Neurocrine Biosciences' rare disease positioning and long term treatment responsibility across a patient’s lifespan. We will examine how...

      Oct 24Yahoo FinanceNBIX
      Neurocrine Biosciences (NBIX) Starts Phase 2 Alzheimer’s Trial
      Oct 23Yahoo FinanceNBIX
      Neurocrine Biosciences Initiates Phase 2 Study of Investigational Compound to Treat Alzheimer's Disease
      Oct 20Yahoo FinanceNBIX
      Neurocrine starts phase 2 trial of Alzheimer’s drug candidate
      Oct 20Investing.comNBIX
      Wedbush Cuts Price Target on Neurocrine Biosciences to $186 From $194, Keeps Outperform Rating
      Oct 19Yahoo FinanceNBIX
      Neurocrine Biosciences (NBIX) Stock Trades Below Fair Value On Earnings

      Neurocrine Biosciences shares have pulled back in recent weeks after a multi year climb, which puts a spotlight on whether the current price around US$135 still lines up with what the business is earning. For anyone tracking the stock, the real issue is how that recent market mood squares with the underlying profit engine. Over the past 5 years the stock has returned about 31%, so a lot of the long term optimism about Neurocrine Biosciences is already embedded in the valuation debate. Fresh...

      Oct 16Yahoo FinanceNBIX
      Neurocrine presents data on congenital adrenal hyperplasia impacts
      Oct 16Investing.comNBIX
      TD Cowen reiterates Neurocrine Bio stock rating on growth outlook
      Oct 14Investing.comNBIX
      RBC Capital Sticks to Its Buy Rating for Neurocrine (NBIX)

      Detailed price information for Neurocrine Bioscienc (NBIX-Q) from The Globe and Mail including charting and trades.

      Oct 14The Globe and MailNBIX
      This Biopharma Stock Offers Compelling Upside After a Pullback

      Neurocrine Biosciences has retreated from its all-time high, creating a buying opportunity for the next phase of growth.

      Oct 14Barron'sNBIX
      Axsome Therapeutics (AXSM) vs. Neurocrine Biosciences (NBIX): Is Faster Growth Worth Paying More For?
      Oct 13Yahoo FinanceAXSMNBIX
      Neurocrine Biosciences' Vykat XR Sales Likely to Remain 'Flattish' Near Term, RBC Says
      Oct 13Yahoo FinanceNBIX
      Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results
      Oct 12Yahoo FinanceNBIX
      Analysts Are Bullish on Top Healthcare Stocks: Argenx Se (ARGX), Neurocrine (NBIX)

      Detailed price information for Neurocrine Bioscienc (NBIX-Q) from The Globe and Mail including charting and trades.

      Oct 10The Globe and MailARGXNBIX
      Analysts Offer Insights on Healthcare Companies: AngioDynamics (ANGO), Neurocrine (NBIX) and DENTSPLY SIRONA (XRAY)

      Detailed price information for Angiodynamics Inc (ANGO-Q) from The Globe and Mail including charting and trades.

      Oct 10The Globe and MailANGONBIXXRAY
      RBC Capital Reaffirms Their Buy Rating on Neurocrine (NBIX)

      Detailed price information for Neurocrine Bioscienc (NBIX-Q) from The Globe and Mail including charting and trades.

      Oct 10The Globe and MailNBIX
      Analysts Have Conflicting Sentiments on These Healthcare Companies: Tango Therapeutics (TNGX), Neurocrine (NBIX) and United Therapeutics (UTHR)

      Detailed price information for United Therapeutic (UTHR-Q) from The Globe and Mail including charting and trades.

      Oct 2The Globe and MailNBIXTNGX
      Neurocrine to present Prader-Willi syndrome research at FPWR event
      Sep 30Investing.comNBIX
      UBS cuts Neurocrine Biosciences stock price target to $214 on competition
      Sep 29Investing.comNBIX
      Neurocrine Biosciences names Eiry Roberts as chief medical officer
      Sep 28Investing.comNBIX
      Neurocrine Biosciences Names Eiry Roberts Chief Medical Officer
      Sep 28Yahoo FinanceNBIX
      Neurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical Officer
      Sep 28BarchartNBIX
      Neurocrine Maps AI, China and Pipeline Strategy as INGREZZA Faces 2029 Price Hit
      Sep 23Yahoo FinanceNBIX

      This is the newest page. Registered accounts read further back.